RxDoctor Payments DataLook up a doctor →

Sharee Chance-Lawson, DO

Family Medicine · Mt Pleasant, WINPI 1659498822

Payments from drug & device makers

$13,039in general payments, 2019–2025

Across 563 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • AbbVie$2K
  • Lilly USA, LLC$974
  • Pfizer$665
  • Boehringer Ingelheim$523
  • plus $6K from 52 others

What the payments were for

  • Food & beverage$12,70797%
  • Education$3323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk85$1,899
AstraZeneca56$1,757
AbbVie(2 entities)77$1,668
Lilly USA, LLC56$974
Pfizer26$665
Boehringer Ingelheim22$523
Otsuka America Pharmaceutical, Inc.23$397
Johnson & Johnson17$388
Amgen18$384
GSK19$372
Axsome Therapeutics, Inc.12$371
Astellas Pharma US Inc14$369
Sanofi-aventis U.S. LLC9$292
Dexcom, Inc.9$267
Coloplast2$216
Merck10$166
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC10$150
Corium, LLC2$144
Takeda Pharmaceuticals U.S.A., Inc.8$133
Amarin Pharma, Inc.4$128
Medtronic2$126
Biohaven Pharmaceuticals, Inc.2$121
Exact Sciences7$114
Neurocrine Biosciences, Inc.5$109
E.r. Squibb & Sons, L.L.C.1$107
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$94
Bayer4$72
Alkermes, Inc.3$72
Sanofi Pasteur Inc.4$66
Lundbeck LLC4$65
Biohaven Pharmaceutical Holding Company Ltd.4$58
Vertex1$56
Nestle Healthcare Nutrition Inc.4$55
Sumitomo Pharma America, Inc.3$54
Seqirus USA Inc2$46
Idorsia Pharmaceuticals US Inc3$46
Mylan Specialty L.p.3$41
Kowa Pharmaceuticals America, Inc.3$41
Vanda Pharmaceuticals Inc.2$41
Daiichi Sankyo Inc.2$38
Ardelyx, Inc.2$38
Madrigal Pharmaceuticals2$35
Teva Pharmaceuticals USA, Inc.1$26
Melinta Therapeutics, LLC1$25
Optinose US, Inc.1$21
Agile Therapeutics, Inc.1$20
Amphastar Pharmaceuticals, Inc.1$19
Eisai Inc.1$18
IBSA Pharma Inc.1$18
Phathom Pharmaceuticals, Inc.1$18
Ironwood Pharmaceuticals, Inc1$16
Neos Therapeutics, LP1$16
Supernus Pharmaceuticals, Inc.1$16
Currax Pharmaceuticals LLC1$15
Ironshore Pharmaceuticals Inc.1$15
Xeris Pharmaceuticals, Inc.1$14
Electronic Waveform Lab, Inc.1$13
Novartis1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,039 in reported general payments places this provider in the 95th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$32,000
Medicare patients
89
Services billed
376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$92,885
JardianceEmpagliflozin40$51,496
FarxigaDapagliflozin Propanediol56$45,469
LinzessLinaclotide40$34,108
MounjaroTirzepatide28$31,725
EliquisApixaban23$28,152
TradjentaLinagliptin19$14,007
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,374
VascepaIcosapent Ethyl20$11,090
TrintellixVortioxetine Hydrobromide14$10,954
Trijardy XrEmpaglifloz/Linaglip/Metformin13$10,675
MyrbetriqMirabegron15$10,476
SynjardyEmpagliflozin/Metformin Hcl14$8,776
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,600
VeozahFezolinetant14$7,829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,899$92,88568 claims
Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Synjardy, Spiriva Respimat$523$91,81999 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,757$56,95981 claims
AbbVieLinzess, Synthroid$1,668$36,45858 claims
Lilly USA, LLCMounjaro, Humulin N$974$32,95243 claims
PfizerEliquis$665$28,15223 claims
Astellas Pharma US IncMyrbetriq, Veozah$369$18,30529 claims
GSKTrelegy Ellipta$372$13,37417 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$133$10,95414 claims
Sumitomo Pharma America, Inc.Gemtesa$54$6,11713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Mt Pleasant

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →